{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:08:57Z","timestamp":1774649337425,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmogo.2024.100083","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T14:45:33Z","timestamp":1721918733000},"page":"100083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-1962","authenticated-orcid":false,"given":"C.","family":"Casadio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Galvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-5721","authenticated-orcid":false,"given":"A.","family":"De Giglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-1690","authenticated-orcid":false,"given":"C.","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Tardio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Melotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sperandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-1728","authenticated-orcid":false,"given":"F.","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-0788","authenticated-orcid":false,"given":"F.","family":"Comito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmogo.2024.100083_bib1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3390\/diagnostics12092091","article-title":"Immune-related uncommon adverse events in patients with cancer treated with immunotherapy","volume":"12","author":"Albarr\u00e1n-Artahona","year":"2022","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100083_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.amjms.2022.02.010","article-title":"Delayed hemorrhagic gastritis caused by immunotherapy in a patient with metastatic melanoma","volume":"364","author":"Elmasry","year":"2022","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.esmogo.2024.100083_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpg.2020.101703","article-title":"Immunotherapy induced enterocolitis and gastritis \u2013 what to do and when?","volume":"48-49","author":"Cheung","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.esmogo.2024.100083_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"36","key":"10.1016\/j.esmogo.2024.100083_bib5","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100083_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100083_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A\u00a0review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100083_bib9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100083_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/CMR.0000000000000502","article-title":"Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma","volume":"28","author":"Yip","year":"2018","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100083_bib11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jgh.15248","article-title":"Gastrointestinal: recurrence of pembrolizumab-induced severe gastritis after tapering steroid therapy","volume":"36","author":"Okubo","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100083_bib12","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1111\/jgh.15427","article-title":"Gastrointestinal: severe gastritis with complete gastric mucosal sloughing","volume":"36","author":"Nasser","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100083_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.gie.2017.04.033","article-title":"Acute hemorrhagic gastritis after nivolumab treatment","volume":"86","author":"Kobayashi","year":"2017","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100083_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100083_bib15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2020.7675","article-title":"Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor\u2013related esophagitis","volume":"19","author":"Panneerselvam","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100083_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/iju5.12568","article-title":"A\u00a0case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma","volume":"6","author":"Fukiishi","year":"2023","journal-title":"IJU Case Rep"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100083_bib17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s12328-020-01218-0","article-title":"A\u00a0rare case of immunotherapy-induced cholangitis and gastritis","volume":"13","author":"Fujii","year":"2020","journal-title":"Clin J Gastroenterol"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100083_bib18","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3390\/cancers14092300","article-title":"Proton pump inhibitor use and efficacy of nivolumab and ipilimumab in advanced melanoma","volume":"14","author":"Homicsko","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.esmogo.2024.100083_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810292","article-title":"Impact of baseline versus intercurrent steroids administration on upfront chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC)","volume":"23","author":"De Giglio","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100083_bib20","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3390\/cancers12102827","article-title":"Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI)","volume":"12","author":"De Giglio","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100083_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmogo.2024.100083_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors \u2013 a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100083_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1754-9485.13390","article-title":"18F-FDG PET\/CT features of immune-related adverse events and pitfalls following immunotherapy","volume":"66","author":"Cherk","year":"2022","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100083_bib24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41598-020-79397-6","article-title":"Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events","volume":"11","author":"Matsukane","year":"2021","journal-title":"Sci Rep"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982400044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982400044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T11:43:34Z","timestamp":1726832614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294981982400044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":23,"alternative-id":["S294981982400044X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100083","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100083"}}